Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 334Carcinoma, Non-Small-Cell Lung 262Ovarian Neoplasms 177Lung Neoplasms 129Neoplasms 92Fallopian Tube Neoplasms 77Carcinoma, Ovarian Epithelial 63Neoplasm Metastasis 59Esophageal Neoplasms 58Stomach Neoplasms 49Head and Neck Neoplasms 45Squamous Cell Carcinoma of Head and Neck 44Triple Negative Breast Neoplasms 40Endometrial Neoplasms 37Adenocarcinoma of Lung 32Urinary Bladder Neoplasms 28Esophageal Squamous Cell Carcinoma 26Unspecified Adult Solid Tumor, Protocol Specific 24Uterine Cervical Neoplasms 23Carcinoma 23Melanoma 22Breast Neoplasms, Male 22Small Cell Lung Carcinoma 20Prostatic Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 20Adenocarcinoma Of Esophagus 20Recurrence 19Brenner Tumor 18Adenocarcinoma, Bronchiolo-Alveolar 18Peritoneal Neoplasms 16

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Solid Cancers × Paclitaxel × Clear all
NCT00954642 2017-05-17

A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
24 enrolled

Solid Cancers

NCT01075464 2016-11-02

A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
64 enrolled

Solid Cancers

NCT01301716 2016-11-02

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Genentech, Inc.

Phase 1 Completed
75 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡